14:44 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest stimulating cholesterol efflux in phagocytes by promoting LXR expression could help treat MS. In a mouse model of lysolecithin-induced MS, cholesterol accumulation in the membranes of lesion-infiltrating phagocytes was...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
20:40 , Jan 5, 2018 |  BC Week In Review  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
23:32 , Jan 4, 2018 |  BC Extra  |  Preclinical News

Cholesterol efflux in phagocytes may promote remyelination

A report published in Science suggests stimulating cholesterol efflux in phagocytes may promote remyelination in aged individuals, offering a potential regenerative strategy for patients who have had multiple sclerosis or other demyelinating disorders for long...
23:19 , Dec 26, 2017 |  BC Extra  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
18:45 , Oct 20, 2017 |  BioCentury  |  Finance

Fast inflections

Longitude Capital joined Cydan Development Inc.’s syndicate with the expectation that spinouts from the rare disease accelerator can deliver returns within three to five years. The company sources rare disease assets from academia, not-for-profits and...
00:34 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million on Oct. 17 in a round led by existing investor New Enterprise Associates (NEA). New investor...
22:58 , Oct 17, 2017 |  BC Extra  |  Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million in a round led by existing investor New Enterprise Associates (NEA). New investor Longitude Capital and...
22:34 , Apr 7, 2017 |  BioCentury  |  Finance

Right place, right time

The takeout of Vtesse Inc. by Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) filled gaps for each company while giving Vtesse investors an exit and a share of any upside. The Vtesse team will get the resources it...
22:38 , Apr 6, 2017 |  BC Week In Review  |  Company News

Vtesse, Sucampo deal

Sucampo acquired rare disease company Vtesse for $200 million. Vtesse shareholders are to receive $170 million in cash and 2.8 million Sucampo shares up front, plus mid-single to double-digit royalties. Sucampo will gain Vtesse's lead...